EquityZen Growth Technology Fund LLC - Series 2282
Raised
$490K
Investors
—
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2282 is a private equity vehicle filed June 23, 2026, claiming exemptions under Rules 506(b), 506(c), 504, and 4(a)(5). The filing reflects a pre-open status with no capital raised, investor count, or minimum investment disclosed. This entity is part of the EquityZen platform, which operates 168+ related EDGAR entities focused on secondary market access to private growth-stage technology companies.
This filing fits the EquityZen SPV model: special-purpose vehicles created for individual secondary transactions in late-stage private companies. The multi-exemption structure (506(b), 506(c), 504, 4(a)(5)) is consistent with the platform's flexible approach to investor onboarding across accredited and potentially sophisticated non-accredited participants. Historical EquityZen series vehicles have raised between $145K and $857K, suggesting modest, transaction-specific capitalization.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govIs this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
